AstraZeneca | AZN - Sales Revenues

Stock Price
13,685.00
Daily Change
-215.00 -1.55%
Monthly
-6.92%
Yearly
27.56%
Q2 Forecast
13,721.54

AstraZeneca reported $15.29B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Alcon AG USD 2.7B 110M Dec/2025
Almirall EUR 547.63M 12.83M Dec/2025
Amgen USD 9.9B 340M Dec/2025
argenx SE USD 1.12B 132.91M Dec/2025
AstraZeneca USD 15.29B 213M Mar/2026
Autolus Therapeutics Ltd USD 24.29M 1.68M Dec/2025
Bayer EUR 11.44B 1.78B Dec/2025
Biogen USD 2.28B 250M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Fresenius EUR 5.88B 400M Dec/2025
Fresenius Medical Care EUR 5.07B 180M Dec/2025
Galapagos EUR 900.82M 835.52M Dec/2025
Genmab DKK 1.06B 36M Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 7.63B 991M Mar/2026
GRIFOLS EUR 1.98B 110M Dec/2025
Haleon GBP 2.86B 110M Mar/2026
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Lonza CHF 3.58B 63M Jun/2025
Merck EUR 5.25B 70M Dec/2025
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.11B 226M Mar/2026
Orion EUR 417.7M 277.6M Mar/2026
Pfizer USD 17.58B 880M Dec/2025
Philips EUR 5.1B 797M Dec/2025
Recordati EUR 662M 37.65M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.24B 60M Mar/2026
UCB EUR 4.25B 764M Dec/2025